Virus Or Bacteriophage Patents (Class 424/93.6)
-
Publication number: 20110256103Abstract: The subject the present invention is a method of producing a pharmacologically stable form of purified and lyophilised bacteriophage preparations of increased stability and antibacterial activity, characterised in that phages produced from a bacterial lysate, for example by ultrafiltration on ultrafiltration membranes, containing a high molecular weight preparation of purified phages is stabilised most preferably with a probiotic extract in the presence or absence of neutral salts and/or organic solvents, lyophilised, characterised via HPLC chromatography, by SDS-PAGE, and bacterial lysis biological assays, and then stored under a vacuum, where the active lyophilisate is destined for phage therapy of infections and tumours.Type: ApplicationFiled: October 29, 2009Publication date: October 20, 2011Inventors: Ewa Zuziak, Andrzej Gamian, Andrzej Gorski, Tomasz Lipinski
-
Publication number: 20110256104Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: ApplicationFiled: May 13, 2011Publication date: October 20, 2011Applicants: CALANDO PHARMACEUTICALS, INC., CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie Bellocq, Jianjun Cheng
-
Publication number: 20110250188Abstract: The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.Type: ApplicationFiled: October 8, 2009Publication date: October 13, 2011Inventors: Dorothee Von Laer, Tsanan Heimann
-
Publication number: 20110250243Abstract: Poly(ethylene carbonate) (PEC) nanoparticles comprising pharmacologically active substances, their production method and their use for sustained release of the pharmacologically active agent after application are described.Type: ApplicationFiled: December 14, 2009Publication date: October 13, 2011Inventors: Thomas Kissel, Holger Petersen
-
Patent number: 8034552Abstract: The present invention relates to virulent (lytic) Listeria monocytogenes phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and/or to the infrastructure of the food processing plants within which such food products are processed, or the containers or wraps in which such foods are stored and/or shipped, in order to reduce Listeria monocytogenes contamination. P100 can also be used in the present invention to identify Listeria monocytogenes bacteria present on (or within) foodstuffs, as well as those Listeria monocytogenes bacteria present in the equipment or the general environment of the food processing plants in which the foodstuffs are being processed and in animals infected with Listeria monocytogenes. The phage and the endolysin of the present invention can also be used to treat animals infected with Listeria monocytogenes.Type: GrantFiled: August 28, 2008Date of Patent: October 11, 2011Assignee: E.B.I. Food Safety B.V.Inventors: Martin Loessner, Richard Carlton
-
Patent number: 8034356Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.Type: GrantFiled: September 28, 2010Date of Patent: October 11, 2011Assignee: Bavarian Nordic A/SInventors: Anton Mayr, Barbara Mayr
-
Patent number: 8034333Abstract: Unique Solenopsis invicta viruses (SINV) have been identified and their genome sequenced. Oligonucleotide primers have been developed using the isolated nucleic acid sequences of the SINV. The viruses are used as a biocontrol agent for control of fire ants.Type: GrantFiled: July 20, 2007Date of Patent: October 11, 2011Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Steven Valles, Roberto M Pereira, Wayne B Hunter, David H Oi, Charles A Strong, Phat M Dang, David F Williams
-
Publication number: 20110243896Abstract: The invention relates to virology and the prevention and/or treatment of viral infection and disease in animals, including birds and humans. The invention relates to the field of antiviral treatments. The invention further relates to methods of stimulating innate immunity and natural interferon production in humans or animals and in component parts of humans or animals, including cells and tissues. The invention also relates to the field of defective interfering (DI) viruses, including cloned DI viruses.Type: ApplicationFiled: December 8, 2009Publication date: October 6, 2011Inventors: Nigel Dimmock, Andrew Easton
-
Publication number: 20110243996Abstract: This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration.Type: ApplicationFiled: April 1, 2011Publication date: October 6, 2011Applicants: Medlmmune, LLC, The Regents of the University of ColoradoInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Publication number: 20110243890Abstract: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.Type: ApplicationFiled: May 17, 2011Publication date: October 6, 2011Applicant: ONCOLYTICS BIOTECH INC.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Publication number: 20110243897Abstract: The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups.Type: ApplicationFiled: December 11, 2008Publication date: October 6, 2011Inventors: Leonard William Seymour, Karel Ulbrich
-
Publication number: 20110229579Abstract: The present invention relates to supports for bioassays and the use thereof in cell culturing and in cell-based methods and assays. More precisely, the invention provides solid materials coated with films of nanostructured titanium dioxide suitable for the immobilisation of viruses and for cell-adhesion. The nanostructured TiO2 film-coated support of the invention is particularly useful for the preparation of microarrays for genetic and phenotypic analysis.Type: ApplicationFiled: May 27, 2011Publication date: September 22, 2011Inventors: Roberta Carbone, Pier Giuseppe Pelicci, Paolo Milani, Paolo Piseri, Emanuele Barborini, Gero Antonio Bongiorno
-
Patent number: 8021657Abstract: The present invention relates to phage isolates having a strong lytic activity against pathogenic Enterobacteriaceae such as Escherichia coli and/or Salmonella strains and their use in various human or pet food products for the treatment or prevention of bacterial diseases caused by pathogenic Enterobacteriaceae such as Escherichia coli, in particular for phage therapy of pediatric gastroenteritis, or Salmonella infection. It also relates to human or pet food products prepared thereof.Type: GrantFiled: September 24, 2009Date of Patent: September 20, 2011Assignee: Nestec S.A.Inventors: Harald Bruessow, Sandra Chennoufi, Josette Sidoti, Anne Bruttin
-
Publication number: 20110223153Abstract: The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be into 3-dimentional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels.Type: ApplicationFiled: October 9, 2009Publication date: September 15, 2011Applicant: TRUSTEES OF TUFTS COLLEGEInventors: Shenzhou Lu, Xiaoqin Wang, Fiorenzo Omenetto, David Kaplan
-
Patent number: 8017110Abstract: A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the fluid to light of an appropriate wavelength to damage the nucleic acid of the pathogen and to substantially maintain the damage to the pathogenic nucleic acids to allow for subsequent transfusion into a recipient.Type: GrantFiled: June 8, 2011Date of Patent: September 13, 2011Assignee: CaridianBCT Biotechnologies, LLCInventors: Raymond P. Goodrich, Shawn D. Keil, Robert Owen Lockerbie, Vijay Kumar
-
Publication number: 20110217268Abstract: A therapy or prophylaxis of K. pneumoniae infections with a lytic bacteriophage specifically against K. pneumoniae, provides a lytic bacteriophage (DSMZ 24329) to a K. pneumoniae infected organism for the sake of relieving the serious complications of liver abscesses and bacteremia, and the high mortality rate of K. pneumoniae infections in Taiwan.Type: ApplicationFiled: January 7, 2011Publication date: September 8, 2011Inventors: Nina TSAO, Chih-Feng Kuo, Chih-Hsin Hung
-
Publication number: 20110212162Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.Type: ApplicationFiled: February 10, 2011Publication date: September 1, 2011Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
-
Publication number: 20110206639Abstract: Described is a replication competent virus, being capable to replicate and having lytic capacity in host cells, the virus comprising in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the said host cells, operably linked to one or more expression control sequences, functional in the said host cells, and the use thereof in the preparation of a medicament and to the use thereof in a method for lysing host cells expressing a virus inhibitory factor.Type: ApplicationFiled: September 3, 2010Publication date: August 25, 2011Inventors: Christie Vermeulen, Victor Willem van Beusechem, Jan Eduard Carette
-
Publication number: 20110200561Abstract: Disclosed are methods of selecting wide host range bacteriophage capable of growing in a plurality of bacteria including pathogenic and non-pathogenic bacteria and bacteriophage selected by the methods. Also disclosed are methods of treating a subject infected with a pathogenic bacterium using bacteriophage and methods of decontaminating objects using bacteriophage. Also disclosed are methods of producing vaccines. In another aspect, methods of determining bacterial viability and methods of improving the sensitivity of a biosensor using wide host range bacteriophages are disclosed.Type: ApplicationFiled: April 21, 2011Publication date: August 18, 2011Applicants: Board of Trustees of the University of Arkansas, United States of America, as represented by the Secretary of AgricultureInventors: Billy M. Hargis, Stacy E. Higgins, Lisa Bielke, Guillermo L. Tellez, Lisa A. Newberry, Gerardo Nava, Ann M. Donoghue, Daniel J. Donoghue
-
Publication number: 20110200556Abstract: Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal. An example of such inhibitor is rapamycin.Type: ApplicationFiled: August 20, 2009Publication date: August 18, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH E SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIInventors: J. Silvio Gutkind, Panomwat Amornphimoltham, Vyomesh Patel, Alfredo Molinolo, Rakefet Czerninski
-
Publication number: 20110195052Abstract: The present invention provides methods of improving the osteogenic and/or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and/or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions.Type: ApplicationFiled: January 18, 2011Publication date: August 11, 2011Inventors: Keyvan Behnam, Christopher Cioffi
-
Publication number: 20110195053Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.Type: ApplicationFiled: April 20, 2011Publication date: August 11, 2011Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CRUSADE LABORATORIES LIMITED, WISTAR INSTITUTEInventors: Susanne M. Brown, Alasdair R. Maclean, Nigel W. Fraser, Bruce P. Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk
-
Patent number: 7993924Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: GrantFiled: September 6, 2007Date of Patent: August 9, 2011Assignee: Crucell Switzerland AGInventors: Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
-
Publication number: 20110189263Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.Type: ApplicationFiled: January 30, 2009Publication date: August 4, 2011Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
-
Publication number: 20110182948Abstract: The present invention relates to the use of a filamentous agent other than a filamentous bacteriophage to disaggregate aggregated proteins in plaque or to treat a patient suffering from or susceptible to a disease characterized by the presence of plaque.Type: ApplicationFiled: May 22, 2009Publication date: July 28, 2011Inventors: Beka Solomon, Oded Grinstein, Nir Friedman, Michal Arbel, Haim Tsubery, Richar Fisher
-
Publication number: 20110182863Abstract: The invention relates to anti-bacterial compositions comprising bacteriophage (phage) in sufficiently high concentrations to induce lysis from without in bacteria. Uses of such compositions are disclosed. Phase K and/or P68 are especially preferred.Type: ApplicationFiled: October 3, 2008Publication date: July 28, 2011Inventor: Ying Jia
-
Publication number: 20110182865Abstract: Provided are compositions and methods for treatment and/or prophylaxis of EHV-I infections in horses. The compositions and methods effect treatment and/or prophylaxis of EHV-I infections through RNAi mediated inhibition of EHV-I gB and EHV-I Ori genes, which results in a reduction of the severity of neurological symptoms that are induced by EHV-I infection in horses, and/or a reduction in EHV-I viral shedding in the horses. Included are siRNAs or shRNAs that are designed to target EHV-I gB and EHV-I Ori helicase mRNAs. Also included are vectors encoding such shRNAs.Type: ApplicationFiled: February 9, 2009Publication date: July 28, 2011Inventors: Nikolaus Osterrieder, Gerlinde Van De Walle, Sarah T. Peters
-
Publication number: 20110182864Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: ApplicationFiled: July 29, 2010Publication date: July 28, 2011Applicants: CALIFORNIA INSTITUTE OF TECHNOLOGY, CALANDO PHARMACEUTICALS, INC.Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie C. Bellocq, Jianjun Cheng
-
Publication number: 20110177037Abstract: A Unique Solenopsis invicta viruse (SINV2) have been identified and its genome sequenced. Oligonucleotide primers have been developed using the isolated nucleic acid sequences of the SINV2. The virus is used as a biocontrol agent for control of fire ants.Type: ApplicationFiled: January 7, 2011Publication date: July 21, 2011Inventors: Steven M. Valles, Charles A. Strong, Yoshifumi Hashimoto
-
Publication number: 20110171262Abstract: Parvoviral capsid with incorporated Gly-Ala repeat region The present invention provides a nucleic acid construct comprising a nucleic acid sequence encoding a parvoviral VP1, VP2 and VP3 capsid proteins comprising an immuno evasion repeat sequence. In addition, the present invention provides a cell comprising such construct, a parvoviral virion comprising a capsid protein that comprises an immune evasion repeat sequence, use of that parvoviral virion in gene therapy and a pharmaceutical composition comprising such parvoviral virion.Type: ApplicationFiled: June 17, 2009Publication date: July 14, 2011Inventors: Andrew Christian Bakker, Valerie Sier-Ferreira, Sebastiaan Menno Bosma
-
Publication number: 20110171239Abstract: This invention provides for compositions, methods and devices for rapidly converting silk fibroin solution into a silk fibroin gel using direct application of voltage, in a process called electrogelation. The silk fibroin gel may be reversibly converted back to liquid form by applying reverse voltage or may be converted further to ?-sheet structure by applying shear force or other treatments. The electrogelated silk may be used as an extracted bulk gel, spray or stream of gel for processing into materials or devices, or may be used as silk gel coating to devices. Active agents may be embedded in the silk gel for various medical applications. This invention also provides for methods and compositions for preparing adhesive silk pH-gels. For example, the method comprises reducing pH level of a silk fibroin solution to increase the bulk or local proton concentration of the silk fibroin solution, thereby forming adhesive silk gels.Type: ApplicationFiled: December 21, 2010Publication date: July 14, 2011Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Tuna Yucel, Tim Jia-Ching Lo, Gary G. Leisk
-
Publication number: 20110171264Abstract: An aqueous composition which comprises a protein or other biological molecule and also (i) optionally comprises one or more metal ions at a concentration of 0.01 to 20 mM; (ii) comprises excipients which are weak ligands; and (iii) is substantially free of excipients which are medium-strength ligands or strong ligands.Type: ApplicationFiled: October 28, 2010Publication date: July 14, 2011Inventor: Jan Jezek
-
Patent number: 7972773Abstract: The invention is directed to a method for detecting low concentrations of bacteria in liquid solution that may or may not be complex liquid solutions. In one embodiment, immunomagnetic separation (IMS) is used to separate target bacterium that may be in a liquid mixture from other constituents in the mixture. A low concentration of a bacteriophage for the target bacteria is subsequently used to infect target bacterial cells that have been captured using the IMS technique. If at least a certain concentration of target bacterium are present, the bacteriophage will multiply to a point that is detectable. Matrix assisted laser desorption ionization/time-of-flight-mass spectrometry (MALDI/TOF-MS) is then used to produce a mass spectrum that is analyzed to determine if one or more proteins associated with the bacteriophage are present, thereby indirectly indicating that target bacterium were present in the liquid mixture.Type: GrantFiled: January 23, 2007Date of Patent: July 5, 2011Assignee: Colorado School of MinesInventors: Angelo J. Madonna, Kent J. Voorhees, Jon C. Rees
-
Publication number: 20110158952Abstract: The invention includes methods of treating an HPV-mediated disease by administration to an individual of a pharmaceutical composition comprising a nucleic acid that encodes a polypeptide comprising an epitope of a naturally occurring HPV protein. The methods include the selection of individuals for treatment with the composition according to a the age of the recipient, as well as the use of the composition to elicit a cross-reactive anti-HPV immune response.Type: ApplicationFiled: June 7, 2010Publication date: June 30, 2011Applicant: EISAI INC.Inventors: Kathleen Beach, Mary Lynne Hedley, Robert G. Urban, Roman M. Chicz
-
Publication number: 20110158953Abstract: Disclosed are compositions and methods relating to Plexin C1 and diagnosing, treating, and evaluating treatment for cancer.Type: ApplicationFiled: June 17, 2009Publication date: June 30, 2011Applicant: UNIVERSITY OF ROCHESTERInventor: Glynis Scott
-
Patent number: 7968101Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.Type: GrantFiled: November 18, 2005Date of Patent: June 28, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Patent number: 7968086Abstract: The present invention relates, in general, to an expression vector and in particular, to a genetically stable viral expression vector.Type: GrantFiled: November 26, 2002Date of Patent: June 28, 2011Assignee: Duke UniversityInventors: Matthias Gromeier, Elena Y. Dobrikova
-
Publication number: 20110152081Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A1, A2 and A3 are independently selected from the group consisting of CR3 and N; B1 B2 and B3 are independently selected from the group consisting of CR2 and N; Q is a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, —CN, —NO2, —N(R4)R5, —C(W)N(R4)R5, —C(O)OR5 and R8; or —S(O)2N(R21)R22, —S(O)pR25 or —S(O)(?NR28)R29; and R1, R2, R3, R4, R5, R8, R21, R22, R25, R28, R29; p and n are as defined in the disclosure.Type: ApplicationFiled: February 28, 2011Publication date: June 23, 2011Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: George Philip Lahm, Kanu Maganbhai Patel, Thomas Francis Pahutski, JR., Benjamin Kenneth Smith
-
Publication number: 20110150926Abstract: The invention relates to a method for the treatment or prevention of an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus.Type: ApplicationFiled: July 31, 2009Publication date: June 23, 2011Inventors: Mohammed Alsharifi, Arno Mullbacher
-
Patent number: 7964186Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.Type: GrantFiled: May 30, 2007Date of Patent: June 21, 2011Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Patent number: 7964397Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: GrantFiled: October 1, 2008Date of Patent: June 21, 2011Assignee: Bavarian Nordic A/SInventors: Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 7964187Abstract: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.Type: GrantFiled: September 8, 2009Date of Patent: June 21, 2011Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Patent number: 7964398Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: July 14, 2010Date of Patent: June 21, 2011Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 7964395Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: August 28, 2008Date of Patent: June 21, 2011Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Publication number: 20110142803Abstract: Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.Type: ApplicationFiled: December 13, 2010Publication date: June 16, 2011Applicant: Ramot At Tel-Aviv University LTD.Inventors: Beka SOLOMON, Orna GOREN
-
Patent number: 7959930Abstract: The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. The invention provides a nucleic acid comprising an influenza gene segment and a bacteriophage polymerase promotor or a complementary strand of said nucleic acid, and a cell comprising such a nucleic acid capable of producing desired influenza virus. Furthermore, the invention provides a composition comprising a cell or material derived from a cell according to the invention and a virus or material derived from a viral particle according to the invention.Type: GrantFiled: December 22, 2005Date of Patent: June 14, 2011Assignee: Abbott Biologicals B.V.Inventors: Emmie De Wit, Monique I. J. Spronken, Ron A. M. Fouchier, Albert D. M. E. Osterhaus
-
Publication number: 20110129528Abstract: The present invention relates to a chitosan capsule in which a soluble active ingredient is encapsulated in a matrix containing chitosan and phytic acid; a cross-linking method and materials capable of being used in preparing the capsule; and pharmaceutical, food and cosmetic compositions comprising the capsule. The chitosan capsule according to the present invention is prepared via ionic gelation of chitosan as a biodegradable polymer with phytic acid capable of rapidly and effectively forming a cross-linking reaction with the chitosan polymer. The capsule of the present invention shows high encapsulation efficiency for a soluble active ingredient and protects the soluble active ingredient from being damaged in a digestive tract, resulting in improving an in vivo delivery efficiency of a physiologically active material.Type: ApplicationFiled: May 29, 2008Publication date: June 2, 2011Inventors: Ji Yong Park, Chan Min Jeong, Min Kyung Lee, Sung Won Choi, Young Hee Cho, Hoon Ok Jeong
-
Publication number: 20110129446Abstract: A new clone of Newcastle disease virus which is interferon insensitive and has an ICPI between 1.2 and 2.0 and which may be used in the treatment of cancer and other diseases.Type: ApplicationFiled: August 13, 2010Publication date: June 2, 2011Applicant: United Cancer Research InstituteInventors: Laszlo K. Csatary, Christine M. Csatary
-
Publication number: 20110129484Abstract: Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.Type: ApplicationFiled: April 17, 2009Publication date: June 2, 2011Inventors: Jeffrey A. Gelfand, Mark C. Poznansky, Pierre R. Leblanc, Svetlana E. Korochkina
-
Publication number: 20110123501Abstract: The present invention relates to supporting weight management, weight loss and/or to the prevention and/or treatment of metabolic disorders. In particular the present invention relates to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of proteobacteria and/or deferribacteres in the gut. One embodiment of the present invention relates to the use of a primary composition comprising an agent that reduces the amount of proteobacteria, preferably gamma-proteobacteria, even more preferred enterobacteria; and/or deferribacteres in the gut for the preparation of a composition to treat or prevent metabolic disorders, to support weight loss and/or to support weight management.Type: ApplicationFiled: July 25, 2008Publication date: May 26, 2011Applicant: NESTEC S.A.Inventors: Chieh Jason Chou, David Philippe, Christian Darimont, Fabrizio Arigoni, Catherine Mace